hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06308510 id: MEC-2024tba briefTitle: Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-07 date: 2028-07 date: 2024-03-13 date: 2024-03-13 name: Erasmus Medical Center class: OTHER briefSummary: Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish whether aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold value as an additional staging and tumor evaluation method in GC patients. conditions: Gastric Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 63 type: ESTIMATED name: collection additional peritoneal lavage fluid measure: Sensitivity mFast-SeqS measure: DFS measure: Concordance detection rates peritoneal dissemination sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus MC city: Rotterdam zip: 3015GD country: Netherlands name: Jessie Huizer, Drs role: CONTACT phone: +31107034523 email: t.j.huizer@erasmusmc.nl name: Niels Guchelaar role: CONTACT email: n.guchelaar@erasmusmc.nl lat: 51.9225 lon: 4.47917 hasResults: False
nctId: NCT06308497 id: 2024-Q10PREGNANT briefTitle: Adjunctive Periodontal Treatment With Coenzyme Q10 in Association With Probiotics for Pregnant Women overallStatus: ENROLLING_BY_INVITATION date: 2024-03-10 date: 2024-10-15 date: 2024-10-20 date: 2024-03-13 date: 2024-04-26 name: University of Pavia class: OTHER briefSummary: The aim of the study is to assess if probiotic supplementation can be effective in reducing periodontal clinical parameters in a 6-month study on pregnant patients. conditions: Periodontal Diseases conditions: Pregnancy Related studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Double-arm parallel design primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Products will be concealed. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Probiotic Treatment name: Standard Treatment measure: Change in Plaque Index measure: Change in Recession (R) measure: Change in Clinical Attachment Loss (CAL) measure: Change in Bleeding on Probing (BoP) measure: Change in Probing Pocket Depth (PPD) measure: Change in API - Approximal Plaque Index measure: Change in Plaque Control Record (PCR%) measure: Change in Papillary Marginal Gingival Index (PMGI) measure: Change in modified Marginal Gingival Index (mMGI) sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Unit of Dental Hygiene - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia city: Pavia state: Lombardy zip: 27100 country: Italy lat: 45.19205 lon: 9.15917 hasResults: False
nctId: NCT06308484 id: TRR265 C02 FP2 briefTitle: Neuromodulation and Mindfulness Patients With AUD overallStatus: RECRUITING date: 2024-03-20 date: 2027-06-30 date: 2027-06-30 date: 2024-03-13 date: 2024-03-13 name: Charite University, Berlin, Germany class: OTHER name: Medical School Berlin briefSummary: Our primary objective is to integrate tVNS and mindfulness meditation within a structured mindfulness-based relapse prevention (MBRP) program for detoxified alcohol-dependent patients (AD). We aim to determine whether neuromodulation can enhance mindfulness-based relapse prevention compared to mindfulness practice alone. In this context, we will investigate potential changes in the interaction of top-down control and cue reactivity, as well as assess the severity of AUD. Measurements of drinking behavior, cravings, and abstinence rates will be conducted up to three months post-treatment. Our second objective is to examine the causal role of frontal midline theta oscillations (FMΘ) in MBRP and cognitive control. To achieve this, we will first establish closed-loop amplitude-modulated transcranial alternating current stimulation (CLAM-tACS) to selectively modulate FMΘ oscillations during MBRP meditation exercises in AUD patients (2). conditions: Alcohol Dependence studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: SINGLE whoMasked: PARTICIPANT count: 140 type: ESTIMATED name: Transcutaneous vagus nerve stimulation name: Closed-loop AM-tACS measure: Cognitive Control measure: Interoception measure: Cue-Reactivity measure: Heartrate measure: Heartrate Variability measure: Mindfulness measure: Alcohol consumption measure: Dependence Severity (Alcohol Dependence Scale) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Charité - Berlin University of Medicine status: RECRUITING city: Berlin zip: 10117 country: Germany name: Rosenthal role: CONTACT phone: 0049 30 450 517040 lat: 52.52437 lon: 13.41053 hasResults: False
nctId: NCT06308471 id: ege üniversitesi briefTitle: Effect of Baby Massage on Oral Motor Skills of Premature Babies overallStatus: COMPLETED date: 2021-09-01 date: 2023-05-01 date: 2023-05-01 date: 2024-03-13 date: 2024-03-13 name: Ege University class: OTHER briefSummary: This experimental research was conducted in a single-blind, block randomized controlled design type.
Comparative results were evaluated statistically. conditions: Infant, Premature studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Baby massage was applied to the intervention group (20) of the study, and oral stimulation was applied with the Fucile protocol to the control group (20). primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: Professional nurses who evaluate nutrition do not know which group they belong to in the study.
They do not know which group the premature babies are in due to their age. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ACTUAL name: Baby massage was applied to the intervention group (n=20) of the study name: Oral stimulation measure: time for first oral feeding measure: time for full oral feeding measure: discharge time sex: ALL minimumAge: 1 Day maximumAge: 28 Days stdAges: CHILD facility: Ege University city: Izmir state: Bornova zip: 35040 country: Turkey lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06308458 id: P.T.REC/012/003966 briefTitle: Breather Exerciser Trainer on Diaphragmatic Mobility And Thickness overallStatus: COMPLETED date: 2023-03-30 date: 2024-01-01 date: 2024-03-01 date: 2024-03-13 date: 2024-03-13 name: Adly A Adam class: OTHER briefSummary: The purpose of this study is to the effect of the breather exerciser trainer on diaphragmatic mobility and thickness in elderly. conditions: Aging Well studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective pre/ posttreatment, randomized controlled study primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Double masking (Investigator, Outcomes assessor whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: Breather Exerciser Trainer name: Conventional Breathing Exercise measure: Diaphragmatic thickness in millimeters measure: Diaphragmatic mobility in centimeters measure: Functional Capacity measure: Geriatric Quality of life Questionnaire measure: Geriatric Quality of Life sex: ALL minimumAge: 65 Years maximumAge: 75 Years stdAges: OLDER_ADULT facility: Faculty of Physical Therapy city: Giza country: Egypt lat: 30.00808 lon: 31.21093 hasResults: False
nctId: NCT06308445 id: RC31/23/0388 briefTitle: Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis acronym: RAPA-4-PAF overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2029-08 date: 2029-08 date: 2024-03-13 date: 2024-03-13 name: University Hospital, Toulouse class: OTHER briefSummary: The hypothesize of this research is that rapamycin is effective and well-tolerated in teenagers with familial adenomatous polyposis (FAP). Rapamycin could be effective in blocking the formation of adenomas and/or their evolution by decreasing their size and number. Researchers aim to assess the safety profile of rapamycin in FAP adolescents using a 2 low dose regimen. conditions: Familial Adenomatous Polyposis studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Rapamycin measure: Evaluation of the safety profile of two doses of rapamycin in adolescents with Familial Adenomatous Polyposis. measure: Evaluation of the effect of rapamycin on the number of polyps, on the entire colon and by segments (rectum, left colon, transverse colon and right colon) in adolescents suffering from Familial Adenomatous Polyposis measure: Evaluation of the effect of rapamycin on the size of polyps, on the entire colon and by segments (rectum, left colon, transverse colon and right colon) in adolescents suffering from Familial Adenomatous Polyposis. measure: Evaluation of the effect of rapamycin on the size of the largest polyp in each segment (rectum, left colon, transverse colon and right colon) in adolescents with Familial Adenomatous Polyposis sex: ALL minimumAge: 12 Years maximumAge: 17 Years stdAges: CHILD facility: CHU Bordeaux Hôpital Pellegrin city: Bordeaux zip: 33076 country: France name: Raphael Enaud, Dr role: CONTACT phone: +33 5 56 79 98 24 email: raphael.enaud@chu-bordeaux.fr name: Raphaël ENAUD, MD role: PRINCIPAL_INVESTIGATOR lat: 44.84044 lon: -0.5805 facility: CHU Montpellier Hôpital Arnaud de Villeneuve city: Montpellier zip: 34295 country: France name: Laura Kollen, Dr role: CONTACT phone: +33 4 67 33 67 33 email: l-kollen@chu-montpellier.fr name: Laura KOLLEN, MD role: PRINCIPAL_INVESTIGATOR lat: 43.61092 lon: 3.87723 facility: APHP Hôpital Robert Debré city: Paris zip: 75019 country: France name: Jérôme VIALA, Pr role: CONTACT phone: +33 1 40 03 36 83 email: jerome.viala@aphp.fr name: Jérôme VIALA role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: CHU Toulouse Hôpital des Enfants city: Toulouse zip: 31300 country: France name: Emmanuel Mas, Pr role: CONTACT phone: +33 5 34 55 84 45 email: mas.e@chu-toulouse.fr name: Emmanuel MAS, MD role: PRINCIPAL_INVESTIGATOR lat: 43.60426 lon: 1.44367 hasResults: False
nctId: NCT06308432 id: UCAMCFE-00036 briefTitle: Sweat Rate Measurement With a Sensor (Wearable) in Different Climatic Conditions With Road Cyclists. acronym: CYSU overallStatus: RECRUITING date: 2024-02-19 date: 2024-04-12 date: 2024-05-20 date: 2024-03-13 date: 2024-03-13 name: Universidad Católica San Antonio de Murcia class: OTHER briefSummary: Controlled, double-blind, crossover clinical trial with six parallel arms depending on the combination of temperature and humidity (22º and 40% humidity, 35º 40% humidity and 35º and 65% humidity), with two differents intensity, to investigate and validate the physiological use of a sensor in recreational road cyclists. conditions: Sweat studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: SINGLE whoMasked: INVESTIGATOR count: 12 type: ESTIMATED name: Low intensity name: Low temperature name: Low Humidity name: High intensity name: High temperature name: High humidity measure: Sweat measure: Microcapillary Blood measure: Heart Rate measure: Fatigue measure: Temperature on the forehead measure: Temperature in the ear measure: Sleep efficiency measure: Karolinska drowsiness scale sex: MALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Catholic University of Murcia status: RECRUITING city: Murcia zip: 30107 country: Spain name: Fco Javier López Román role: CONTACT phone: 968278523 email: jlroman@ucam.edu lat: 37.98704 lon: -1.13004 hasResults: False
nctId: NCT06308419 id: 2023-0900 id: NCI-2024-01751 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions overallStatus: NOT_YET_RECRUITING date: 2024-07-31 date: 2029-02-01 date: 2031-02-01 date: 2024-03-13 date: 2024-03-15 name: M.D. Anderson Cancer Center class: OTHER name: Aadi Bioscience briefSummary: To find a recommended dose of gemcitabine and nab-sirolimus that can be given in combination to participants with advanced leiomyosarcomas or soft-tissue sarcomas. conditions: Leiomyosarcoma conditions: Soft-tissue Sarcomas studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Gemcitabine name: Nab-Sirolimus measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Elise Nassif, MD role: CONTACT phone: 281-460-0607 email: efnassif@mdanderson.org name: Gracy Zacharian, BSN,MSN,RN role: CONTACT phone: (713) 792-2669 email: gzachari@mdanderson.org name: Elise Nassif, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06308393 id: RSP61418 briefTitle: Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-08 date: 2024-10 date: 2024-03-13 date: 2024-03-13 name: Jiangsu HengRui Medicine Co., Ltd. class: INDUSTRY briefSummary: Randomized, double-blind, placebo-controlled study of RSS0393 ointment in healthy and psoriatic subjects conditions: Healthy conditions: Psoriatic Subjects studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 88 type: ESTIMATED name: RSS0393 ointment；Placebo measure: The percent of Local skin tolerance was assessed as moderate or higher（Single dose in healthy subjects） measure: The percent of Local skin tolerance was assessed as moderate or higher （Multiple dose in healthy subjects） measure: Measurement of blood examination（Multiple dose in patients ） measure: Measurement of urine examination（Multiple dose in patients ） measure: Measurement of Blood Chemistry examination（Multiple dose in patients ） measure: Measurement of coagulation function examination（Multiple dose in patients ） measure: AUC0-t （Single dose in healthy subjects） measure: AUC0-∞（Single dose in healthy subjects） measure: Tmax（Single dose in healthy subjects） measure: Cmax（Single dose in healthy subjects） measure: t1/2（Single dose in healthy subjects） measure: CL/F（Single dose in healthy subjects） measure: Vz/F（Single dose in healthy subjects） measure: AUC0-t （Multiple dose in healthy subjects） measure: AUC0-∞（Multiple dose in healthy subjects） measure: Tmax（Multiple dose in healthy subjects） measure: Cmax（Multiple dose in healthy subjects） measure: t1/2（Multiple dose in healthy subjects） measure: CL/F（Multiple dose in healthy subjects） measure: Vz/F（Multiple dose in healthy subjects） measure: Absolute change in PASI score relative to baseline（Multiple dose in patients ） measure: The percentage change in PASI score relative to baseline（（Multiple dose in patients ） measure: The percentage of PASI50、PASI75、PASI90、PASI100（Multiple dose in patients ） measure: The percentage of subjects' achieving PGA score of 0 or 1 and which improvement ≥ 2 from baseline （Multiple dose in patients ） measure: The percentage of subjects' inPGA score improvement ≥ 2 from baseline（Multiple dose in patients ） measure: Absolute change in BSA score relative to baseline（Multiple dose in patients ） measure: The percentage change in BSA score relative to baseline（Multiple dose in patients ） measure: Pharmacokinetics (PK) : Concentrations of RSS0393（Multiple dose in patients ） measure: Pharmacokinetics (PK) : The major metabolites of RSS0393（Multiple dose in patients ） sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06308380 id: UCV/2022-2023/158 briefTitle: Effectiveness of Rehabilitation Protocol in Patients With Shortened Posterior Leg Muscles acronym: EREPSOLM overallStatus: RECRUITING date: 2024-03-10 date: 2024-07-01 date: 2025-03-10 date: 2024-03-13 date: 2024-04-23 name: Fundación Universidad Católica de Valencia San Vicente Mártir class: OTHER briefSummary: The goal of this clinical study is to develop a specialized rehabilitation exercise protocol designed for patients diagnosed with foot pathologies and calf muscle shortening, regardless of their choice to undergo minimally invasive ultrasound-guided surgery. The primary focus is to assess disparities in outcomes, particularly in the recovery of ankle mobility degrees. Additionally, for patients opting for minimally invasive ultrasound-guided surgery, the study aims to evaluate the resumption of both sporting activities and daily routines using the aforementioned specific rehabilitation protocol.
Researchers will compare participants who undergo minimally invasive ultrasound-guided surgery against those who choose other treatment options to discern any differential effects on ankle mobility recovery and resumption of activities. conditions: Equinus Deformity of Foot conditions: Gastrocnemius Equinus conditions: Contracture studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 40 type: ESTIMATED name: Specific protocol of rehabilitation exercise name: Short gastrocnemius surgery. measure: Gait Analysis measure: Baropodometric examination measure: Passive ankle mobility measure: Short Form Health Survey 36 score measure: Foot Function Index measure: American Orthopedic Foot and Ankle Score measure: Halasi score measure: Olerud and Molander ankle score. measure: Visual Analogue Scale sex: ALL minimumAge: 20 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Podologia Avançada status: RECRUITING city: Granollers state: Barcelona zip: 08401 country: Spain name: Lluis Castillo-Sanchez, Dr role: CONTACT phone: 610143173 email: info@podologiaavanzadabcn.com name: Lluis Castillo, Dr role: SUB_INVESTIGATOR name: Cristina Razzano role: PRINCIPAL_INVESTIGATOR name: Simone Moroni role: SUB_INVESTIGATOR lat: 41.60797 lon: 2.28773 facility: Clinica Mayral foot center status: RECRUITING city: Barcelona state: Barcelon zip: 08029 country: Spain name: Jordi Mayral role: CONTACT phone: (+34) 93 339 78 41 email: barcelona@clinicamayral.com name: Jordi Mayral role: SUB_INVESTIGATOR name: Cristina Razzano role: PRINCIPAL_INVESTIGATOR name: Simone Moroni role: SUB_INVESTIGATOR lat: 41.38879 lon: 2.15899 facility: Clinicas UCV status: RECRUITING city: Valencia state: València zip: 46001 country: Spain name: Pablo Vera-Ivars, Dr. role: CONTACT phone: 963 92 06 24 email: clinicas.ucv@ucv.es name: Cristina Mico-Salcedo role: CONTACT phone: 963 92 06 24 email: clinicas.ucv@ucv.es name: Javier Ferrer-Torregrosa, Dr role: PRINCIPAL_INVESTIGATOR name: Juan Vicente-Mampel, Dr. role: PRINCIPAL_INVESTIGATOR lat: 39.46975 lon: -0.37739 hasResults: False
nctId: NCT06308367 id: XWTEBS briefTitle: The Therapeutic Effect of Betaine in Syringomyelia overallStatus: RECRUITING date: 2024-03 date: 2027-03 date: 2028-03 date: 2024-03-13 date: 2024-03-13 name: Xuanwu Hospital, Beijing class: OTHER briefSummary: Purpose: This clinical trial aims to evaluate the indications, therapeutic effects and side effects of betaine in refractory syringomyelia.
Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before betaine usage. conditions: Syringomyelia studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Betaine name: Placebo measure: ASIA Score measure: syringomyelia remission measure: Electrophysiology results measure: Visual Analog Scale (VAS) measure: Klekamp and Sammi syringomyelia scale measure: modified Japanese Orthopaedic Association Scores (mJOA) measure: xuanwu syringomyelia scale measure: Incidence of complications sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fengzeng Jian status: RECRUITING city: Beijing state: Beijing zip: 100053 country: China name: Yuan Chenghua role: CONTACT email: yuanchenghua@ccmu.edu.cn name: Jian Fengzeng role: CONTACT email: jianfengzeng@xwh.ccmu.edu.cn name: jian guan, dr role: SUB_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06308354 id: CRC dataset briefTitle: Colorectal Cancer Dataset in Xijing Hospital From 2011 overallStatus: RECRUITING date: 2011-01-01 date: 2048-01-01 date: 2048-01-01 date: 2024-03-13 date: 2024-03-13 name: Xijing Hospital class: OTHER briefSummary: To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital. conditions: Prognostic Cancer Model conditions: Chemotherapy conditions: Nutrition Related Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40000 type: ESTIMATED measure: overall survival measure: DFS sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fourth Military Medical University status: RECRUITING city: Xi'an state: Shaanxi country: China name: Jipeng Li role: CONTACT phone: +86-029-84771533 lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06308341 id: REC/RCR&AHS/23/0295 briefTitle: Combined Effects of Virtual Reality and Motor Imagery Techniques With Routine Physical Therapy in Post Stroke Patients overallStatus: RECRUITING date: 2024-02-25 date: 2024-05-19 date: 2024-05-28 date: 2024-03-13 date: 2024-03-13 name: Riphah International University class: OTHER briefSummary: Stroke a devastating neurological condition, causing severe neurological challenges such as balance issues, motor function and cognitive deficits among survivors and can cause disability and death. The use of Virtual Reality and Motor Imagery in rehabilitation of neurologic disorders is on the rise. In stroke patients, VR and MI combination has not been studied. This study aims to investigate the combined effects of Virtual Reality and Motor Imagery Techniques with Routine Physical Therapy in patients with post stroke patients. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient will be allocated whoMasked: OUTCOMES_ASSESSOR count: 75 type: ESTIMATED name: Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy name: Virtual Reality + Routine Physical Therapy name: Motor Imagery +Routine Physical Therapy measure: Berg Balance Scale measure: Fugal-Meyer Scale measure: Barthel Index sex: ALL minimumAge: 40 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Riphah International University status: RECRUITING city: Lahore state: Punjab zip: 54660 country: Pakistan name: Muhammad Kashif, PhD-PT role: CONTACT phone: 03333125303 email: Kashif.shaffi@gmail.com lat: 31.558 lon: 74.35071 hasResults: False